-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Nuocheng Jianhua issued an announcement that the company and Biogen have reached a license and cooperation agreement for the oral small molecule Bruton's tyrosine kinase inhibitor (BTKi) abutinib, which is expected to treat multiple sclerosis (MS).
Obrutinib is a BTK inhibitor with independent intellectual property rights.
Reference source: corporate announcement